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Objectives. This dwbk-blind, randomized, multicenter trial 
WBI designed to compare the efkts of treatment with anirtreptase 
(APSAC) and atkptacr trt.PA) on eoovatoscent left ventricutar 
fun&n, nmrbtdilv and cwonw artery pstency at 1 day in 
patie& with ac&myocardiat inlarctik 
Backgmnd. Anistreplaw (APSAC) is a oew, easily adminis. 
ered thr~lnbolytic agent rwently appmwd r0r thtm or acute 
myacardial infarclion. Alkplise (rl-PA) is a rapidly acting, 
retatiwty tibrinapecik tbrokc4ytt.c agent that is rurreody tbe 
mos# widely wed agent in the United Sales. 
6fe:hcd.s. Stud” entry reauiremm,s were see 575 wm. 
sympbmt duration s4 h;ST &mutt elevatioo aid M) co&‘ain- 
diitims. The two study drugs, APSAC, Jo U/Z to 5 min, and 
rt.PA, 100 mg/3 h, were each given ti,b aspirin I160 mglday) and 
intravenous heparin. Prespwttled end poinb were convatewen, 
left ventrtcula; function (resLxer&d, clinical morbidity and 
mronary artery ps(ency at 1 day. A ,oM of 325 patienls worn 
entered. stratltid in10 IIOUDS with antertor 137Wt or inferior or ~ . 
other (63%) acute myocardial infarction, mndkmd to receive 
APSAC 01 It-PA and lollowed up fm 1 month. 
Results. At entry, patten, thsmcterbtirr in the two grwps 
were balanced. convatacent ej&ttn r-a, the pwdttlwge 
study averaged 51.3% in the APSAC gmap pnd 54.2% in Ihe 
rt.PA group tp < O.wb I, 1 month. ejeato hXt&I aver& 
50.2% versus 54.8%. rqx&sety (p < 0.01). In cwkas,. ejedtca 
fraction showed stmilsr sugmentsticm tik exercise at I madh 
alter AF’SAC (C4.38 poi,t,s) and tl-PA (+4.6% points), sad 
exercise times were wmpambte. Comnary artery patency at 1 day 
was high and rimtlar im both groups @SAC (19% rt-PA 86%). 
Mortality (APSAC 6.2%. r&PA 7.9%) and tk tnctdence ofctber 
serious clinical events, b&ding rtmbe, vetdrtculsr ,achycardtt, 
vetricntar flbdltadt, her( fnilve aiulin 1 m&h, rem-t 
iwbemiaand rti~~tionIr(remmpprpMeiathe(nogmups;and 
mechanical iomVenttor6 sloe apptii with apmt Frequency. A
wmhined clinicd rnwbidity imdex was detemkd and dtowed a 
comparable orcrau a,caoc r0r the twa tlmtmnts. 
Conclusions. Conmtew, red ejeck fraaioo NIX high after 
both therapies hul hi&r atIer rt-PA; other clisical mdmmes, 
including exercise function, morbidity htdax and lday cnmnary 
artery patency, “Ore rnv0Rbk and mmparabte &ner APSAC and 
R-PA. 
,J Am ColI Cardial 1992;20:753-66) 
Substantial pmgress in understanding the pathogenesis of 
acute myocardial infarction and providing effective therapy 
has been made in the past decade. The ceittral role of coronary 
thrombosis. generally triggered by atherosclerotic plaque fis 
wing or ukeration. as a pathogenztic mechanism precipitating 
acute mywsrdial infarction has been established (I .2) and has 
fueled interest in repafusion therapy (M). Clinical trials over 
the pas, several years have estaolisbed coronary thmmbolysis. 
using plasminogen activators, as the mainstay of therapy for 
acute mywardial infarction (5). 
The feasibility of achwng repelfus~on was initially 
shown with intracoronary administration ofthe conventional 
plazminogen aCLiwlors streplokinase and urokinase 16-81. 
Subsequently. intravenous administradon of thrombolytic 
agents ear demonntrated to effectively eslablish coronary 
artery patency (9-12). improve left ventricular funclion 
113-161 and reduce mortalitv 117-20). Recent and current 
&estigative interest has for&d on I) developing improved 
reperfusion regimens, including better thrombolytic agents 
and combinations of agents. more optimal adjunctive medi- 
crd therapies (such as aspirin. heparin. nitroglycerin and 
beta-adrenergic blocking agents) and the most appropriaw 
use of mechanical therapies langiography. angioplasty and 
surgeryl, and 2) providing such therapies to a broader 
category of patients and more rapidly (21-23). 
Anisrreplase (anisoylawd plasminogen streptokinase 
activator complex [APSAC]) and alteplase (recombinant 
tissue-type plarminogen activator [rt-PA]). two second- 
generation thrombolytic agents developed to improve on 
perceived deficiencies or disadvantages of the older standard 
agent, streptokinase. 6:~ now available for clinical use. The 
agent R-PA differs from streptoainase in several ways: it is 
more specific in its aclivity for fibrin than for plasma 
fibrinogen. nonantigenic and possesses a shorter half-life of 
plasma fibrinolytic acfivity (24). The agent APSAC, a I:t 
molar complex of streptokinase and modified (1~s). 
plasminogen, was developed to provide a greater fibrin 
affinity and librinolytic efficiency. a longer plasma half-life 
and a greater ease of admintstration !rS-min injection) than 
are provided by streptokinase and other agents (25.26). 
Although each of the approved thrombolytic agents has 
been extensively and favorably compared with standard 
nonthrombolvtic a~cnts. commxisons amonc diCerent 
thrombolytic ‘agent;. especially APSAC and rl-PA. have 
been fewer 07-311. Studies have acnerallv shown bvoruble 
early patency rates for r&PA l27.?8) and’APSAC 09.301 in 
comparison with that for streptokinase hut have not shown 
advantaaes for these aeen~s wth resow to vemricular 
functioht31) or monalit~(32.33). 
The recent Gruppo ltaliano Per lo Studio delta Streplochi- 
nasi Nell’infarlo Miacardico (GISSII-Z/International Study 
132) failed to show a mortality advantaee of r&PA over 
streptokinase. but that study has been cri&ized for using a 
delayed heparin regimen that many cardiologists believe to 
he suboptimal (34-36). Thrombolytic therapy with APSAC 
and rl-PA has been shown 10 reduce the monalily rate 
observed with placebo (odds reduclion 46% and 29%. re- 
spectively) 137.38). but direct comparisons of agenls are 
needed to establish superiority of one over anolher. The 
Third International Study on infarct Survival (ISIS-I) (33) 
compared the effects of three thrombolytic asents on mor- 
rality. In that study, a different form of iPA (duteplasel was 
compared with APSAC and srreptokinase, and heparin was 
given sabcu!aneous!y rather than intravenacely. the more 
common practice in North America. Because of these con- 
siderations. questions about the relative efficacy of the three 
agents persisl. Smaller bul more thoroughly studied patien! 
gioups’in trial% oriented toward funcuonal asseswnent may 
thus complement the information from these large mortality 
studies by improving underslanding of how thrombolylic 
regimens provide benefit. 
To compare APSAC. recently approved for use in acute 
myocardial infarction. and rt-PA, currently the most widely 
used agent for acute myocardial infarction in the United 
States, we undertook a direct. controlled comparison of the 
approved regimens of these two second-generation throm- 
bolytic agents in patients with acute myocardial infarction. 
The ohjwtive? of the TEAM.3 study were to compare the 
effec~a of APSAC and r&PA on left ventricular function. 
coronary artery patency and morbidity in a carefully can- 
trolled. multicenter study of inlermediate size. The specific 
objectives were I) to compare left ventricular ejection frac- 
tion at rest and during exercise before hospital discharge and 
at I month. 2) to compare the clinical morbidity (relative 
safety) after APSAC and n-PA therapy and the need for 
mechanical interventions. and 3) to assess coronary artery 
patency at I day after dosing. 
Methods 
Experimental design. The study was designed as a dou- 
ble.blind. double-dummv comnarison of APSAC. aiven over 
2 to 5 min. and rt-PA.Sgiven over 3 h. in patients with a 
documented acme myocardial infarction who could undergo 
therapy within 4 h of the onset of symptoms. The patients 
were randomized according to two coded sequences specific 
for each study she-one for anterior and the other for 
inferior or other acute myocardial infarction. Approval by 
the Institutional Review Board at each TEAM site was 
required before study initiation. and individual written con- 
sent was obtained before patient entry into the study. 
Patient selection. A minimum of JM) patients with acute 
myocardial infarction were to he selected for the study from 
the 28 participalina howhaIr. Patients were eltgibte for 
inclusion who-11 had ischemic pain lasting for a36min and 
could be treated within 4 h of its onset: 21 had electrocar- 
diographic (ECG) ST segment elevation in two or more 
contiguous leads that was 90.1 mV in at least one limb lead 
or ~0.2 mV in m lea~l one precordial lead; 3) had chest pain 
and ECG changes that were nor completely relieved by 
intravenous or sublingual adminiwation of nitroglycerin if 
this treatment was not contraindicated: 4) could undergo 
radionuclide ventriculography within 4 h of the start of 
therapy: and 5) gave written informed consent. 
Patients were excluded for the followiw reasons: I) age 
a76 years: 2) aWe internal bleeding or history of hem& 
rhagic dialheris: 31 history tat any tune) of a cerehrovascular 
&dent. inlrxrminl neoplasm. mlerioverxous fiblula or 
aneurysm: 4) recent twhhin 6 months) intracranial or in- 
traspinal surgery or trauma: 5) recent (within 3 months) 
8dstroinlesttttal or genitourinary bleeding; 6) operahon 
within IO days that could predispose to life-threatening 
bleeding; 7) sustained or traumatic external chesl massage 
(e.g., >2 min duration. rib fractures) or other significant 
trauma (e.g.. bead iojjury. traumatic intubationl; 8) recent 
(within 6 months) severe, uncontrolled hypertension: signif- 
icant hypertensive complications (e.g., hypertensive en- 
cephalopathy. lacunar infarction); 9) systolic blood pressure 
>I80 mm Hg or diasrolic blood pressure ,110 mm Hg on 
admission; IO) ongoing cardiogentc snack (systolic blood 
pressure ~80 mm Hg, or pressor or intraaortic balloon 
dependency or Killip class IV status): I I) recetpt oi rtrep- 
tokinase or APSAC within 6 months or severe aiiergic 
reaction to streptokinase, APSAC or r&PA; 12) recent 
history Within I month) of coronary angioplasty or history 
of bypass graft surgery; 13) long-term therapy with full dose 
anticoagulant agents (e.g., warfarin. heparin); 14) prosthetic 
valves. dilated cardiomyopathy or ventricular +neurysm: 
and 1% ore~nancv. lactation or childbearine mwntial. 
Stud; mediea&n and dosing. Both AI%C (Eminase) 
and its matching placebo were prepared by adding 5 ml of 
sterile water 0rGline solution to a vial comainin~ 30 IJ of 
lyophilized powder and were administered by a slow in&+ 
venous injection over 2 to C min. Both n-PA (Activase) and 
its matching placebo were prepared by adding SO ml of sterile 
water without preservative to each of two vials containing 
50 otg of lyophilized powder. For patients weighing a65 kg. 
a dose of 100 ma ClaO ml) was eiven intravenouslv over 3 h: 
lomgwasadministeredasabaiusin I to2min,5~mgduring 
the 1st h, and 20 mglh during the 2nd and 3rd h. For patients 
weighing <65 kg. the total dose was given according to 
weight (that is, 1.25 m&body weight). 
In both therapies, heparin administration was initiated 
with an intravenous bolus dose ofS.tMtl U given 2 h after the 
start of thrombolytic therapy and was continued as an 
intravenous infusion at a rate of I.wO Uilt. Subsequent 
infusion rates were adjusted to maintain the activated partial 
thromhoplastin time at I.5 to 2.5 limes the upper limit of 
norma!. Hepatio administration was continued for ~2 days. 
Aspirin was g&n orally in a dose of IM) ma Wvo 
chewable 80.mg tabI&) immediately on study entry and 
thereafter in a dose of 160 to 320 m&/day un!l: ..: least the 
I-month visit. 
Administration of medications not speciiied by protocol. 
blood trattsfusions and other therapies were based on local 
standards of care or individual patient needs, as determined 
by the individual study investigator. 
Coronary pngio8rapby. Coronary angiography was per- 
formed by using the Judkins or Sones technique at I day (I8 
to 48 h) after the start of thromholytic therapy. Multiple 
angiographic views were obtained. including the optimal 
view for maximizing the degree of stenosis of the infarct- 
related artery and its orthogonal (right angle) complement. 
‘.ontrast left ventticulo8raijhy was also performed at the 
time of attgiography. 
Coronary flow in the infarct-related artery was graded 
accordmg to the Thrombolysis in Myocardial Infarction 
ITIMI) classification 127) of perfusion oo a scale of 0 to 3 by 
bbndcd intcrwetation of the study bv an exoaienced. vali- 
dated reader i39) at the TEAM core angiagr&c laboratory. 
The TIMI perfusion score has been described &whew 
(27.30.391. In brief. grade 0 = complete occlusion to contrast 
flow: erade I lminimal perfusion) = penetration of contrast 
about clot with minimal distal perfosion: grade 2 (partial 
perfusion) = entry or clearance ofcontmst medium, or both, 
into or from the distal coronary bed at a reduced rate: grade 
3 (complete perfusion) = perfusion showing a normal rake of 
entry and clearance. The number of major vessels with 
significant coronary artery disease l&O% lumen diameter 
stenosis) war also determined in a blinded manner by the 
independent reader. 
The degree of residual stenosis of the infarct-related 
coronary ariery was quantified by using a validated rech- 
niquc (40) modified from the method of Brown et al. (4th In 
briei. tine frames of the iofarc-related artery. including two 
high quab!y frames in the optimal view for maximizing the 
stenosis and two in the orthogonal view. were selected for 
analysis in the core labmatory without know!edge of patient 
assignment. The frames were projected (Vanguard M-35 R) 
onto a 24 x 30%. (61 x 81.cm) horizontal screen and !he 
bordem were traced by hand. Tracings of images of stenotic 
and normal ~e8ments and the angiographic catheter of 
knor I diameter were then quantified by using a dipitized 
drawing board and analyzed by using the Configurable 
Measurement System software coupled 10 a personal coot- 
puter. Stenosis was scored as the minimal lumen diameter, 
minimal percent lumen diameter (the “ptimav” quantitative 
measure). minimal lumen area and minimal percent lumen 
area. Data points were derived from averages of duplicate or 
triplicate meawre~ of the optimal views (views of maximal 
stenosis) and their respective orthogonal views. 
Gttidekws for inlenenlions. lo keeping with results of 
studies that assessed the effects of routine aagioplasty after 
rt-PA (42-W and APSAC (45) therapv, a conservative . 
approach to interventions was adopted. Elecrive angioplasty 
was not to be perfumed at the anaiiographic study performed 
at I day in patients with grade 2 or 3 perfusion. Elective 
angioplasty was also not to be routinely performed in the 
absence of clear clinieal indications before the discharge (or 
IO-day) radionuclide ventriculogram/exercise test. Allow- 
ance for emergency angiography. angioplasty and bypass 
surgery was made for I) patients who dewlo@ card&gent 
shock or early hemodynamic failure. and 2) patients who 
developed recurrent. prolonged. rest ischemic pain “ore- 
lieved by nitroglycerin and accompanied by ECG changes 
charactetinic of irchemia. After the l&day and before the 
l-month assessment, an exercise test positive for an isch- 
emit response, 8s judged by individual investigators, was 
allowed as an additional reason for intervention in patients 
with >7o% coronary artery steooses. 
Rndionuclide ventriculogrsphy. Admission (baseline) 
radionuclide ventriculography was performed as soon as 
possible after dosing and within a maximum of 4 h. Conva- 
lescem radionuclide ventriculography was performed 7 to IO 
days after dosing or at the time of hospital discharge, 
whichever came first. and again at I month (3 to 6 weeks 
after dosing). In addition, exercise testing to determine 
exercise left ventricular ejection fraction was performed at 
the 7. to I&day and I-month assessments. t&ted blood pool 
SCBIIS were performed with use of the same eq~.ipment for 
each individual patient in all studies at each center. A 
standardized procedure (46-48) enabled centralized reading 
of ejection fractions and left ventricular volmnes et the 
TEAM core radionuclide laboratory and included recording 
of specified data at the time of imaging, e marker Y~DW for 
calculating attenuation distance and blood sampling and 
counting to allow conversion of left ventricular counts to left 
ventricular vohtmes. individual studies were copied onto 
floppy computer disks by the study centers and sent to the 
core radionuclide laboratory where they were assessed in 
blinded manner (46-48). End-systolic and end-diastolic 
frames were selected manually in blinded manner by the 
observer. Background counts were subtracted by using as a 
region of reference an automatically selected area just lateral 
and inferior to the left ventricular apex in the end-systolic 
tine frame. Corrected end.systolic and end-diastolic cotmts 
were then used to calculate ejection fraction es (End- 
d&c&c - End-systolic countstlEnd-diastolic counts x 100. 
The normal value of the core laboratory for global rest left 
ventricular ejection fraction is zSO%. 
Regional wall motion was determined in the left anterior 
oblique view by using a Ibsector (22S’isector) display 
automatically generated from fixed center points in the 
end-systolic and end-diastolic tine frames. lschemic zone 
sectors on the baseline study were identified in blinded 
fashion and an ischemic zone regional ejection fraction was 
calculated from the regional end-systolic and end-diastolic 
cotmts. Similarly. sectors showing normal or bea wall 
motion outside the ischemic zone were selected on the 
baseline study. and a normal zone regional ejection fraction 
was calculated. These same sectors were then analyzed on 
the discharge and l-month studies to determine convalescent 
ischemic zone and normal zone ejection fractions. 
Absolute left ventricular volumes at end.diastole and 
end-systole were calculated as the ratio of the attenuation- 
corrected end-diastolic and end-systolic count rates from the 
gated blood pool study to the cotmt rate per ml from a blood 
sample. Attenuation correction was made by dividing the 
end-diastolic or end-systolic count rates by exp(-ud). where 
u is the linear attenuation coefficient of water and d is the 
distance from the skin marker to the center of the left 
ventricle in the anterior view divided by sin 40’. to yield the 
depth of the left ventricle in the left anterior oblique view 
(48). 
Clinical, electmcardlogrephic, enzymalic and laboratory 
observatians and exercise tolerance testing. Standard l2.lead 
ECCs were obtained at entry, at 8 h after dosing. at IO days 
(or at hospital discharge. whichever came first1 and at the 
I-month visit. Study entry ws based on local readings of the 
ECG; study results were based on a subsequent analysis 
performed centrally. 
Blood samples were taken for analysis of creatine kinase 
(CK) and its csrdiac isoenzyme (MB CK) before dosing 
and at 4. 8, 12, 24 and 36 h after dosing and for analysis of 
lactate dehydrogenase and its cardiac isoenzyme (LDH-I) 
before dosing and at 12. 24, 36 and 12 b after dosing. Clin. 
ical chemistry and hematologic values were assessed in 
samples taken before dosing and at 24 and 12 h after 
dosing and at hospital discharge (or 10 days). A urine sample 
was collected between 24 and 72 h after dosing for determi- 
nation oi hematuria. Fecal material was tested for occult 
blood on days 1 and 3 and et hospital discharge (or IO days). 
hecial coagulation testing for fibrinogen, plasminogen and 
alpha-,-antiplasmin was performed on blood sampler col- 
lected before dosing and at 4.24 and 48 h after the start of 
dosing; samples were handled in a standardized manner and 
were analyzed et the core coagulation laboratory (49). 
Pulse rate and blood pressure were measured et least 
twice before dosing. at 5. to IO-mitt intervals for 30 min after 
the start of dosing. at least every Ii2 to I h until 3 h and then 
at routine intervals (at least daily) until discharge. Temper- 
ature was measured before dosing, at I2 h and then at least 
daily. Additional clinical observations incltzded soy adverse 
experiences starting or worsening after dosing and before 
discharge. Three conditions were specifically assessed dur- 
ing the hospital stay: heart failure (S, gallop, r&s, radio- 
gnPhic congestion. need for digitalis or diuretic agents), 
recurrent &hernia (typical pain responding to nitroglycerin 
or causing ECG changes), and serious ventricular arrhyth- 
mias tventricular fibrillation or ventricular tachvcardia of 
>I5 beats at >I20 beatsiminl. These and other adverse 
events were assessed and entered independently on case 
report forms by the individual study investigators. who had 
no knowledge of the drug assignment. 
Exercise tolerance t&g was performed by using pm- 
gressive supine bicycle ergometry as part of the exercise 
ventriculogrem et the 7. to IO-day submaximal and l-month 
maximal tolerance test. Exercise was increased every 3 mitt 
in 25-J increments until the clinical end point was reached. 
Unless contraindicated by clinical criteria, beta-blocking 
agents were withheld for 224 hand nitrates for 212 h before 
the convalescent rest/exercise ventriculogmphic stodies 
were performed. 
Statistical consideratienr, F’rimory hypothesis and powr 
crrlcrrlarions. The study was designed to have sufficient 
power to detect e 3% point difference in convalescent 
ejection fraction (at discharge and I month) between trem- 
ment groups. a difference that the investigators judged to be 
of potential clinical significance. On the baGs of previous 
core laboratorv exoerietxe. the standard deviation of eiec- 
lion fraction ii patients receiving thmmbolytic therapy was 
estimated to be 9.2% points (IO. Enrollment of 300 evalu- 
able patients is then required to detect a. ~3% point differ- 
ence with a power (fl) of 8ffk at a stgmficance leve! ttwo- 
tailed test) of p d 0.01. 
Srorisricol mcrhods and niodeling. Comparawe end 
points were predefined and ordered BR hollows: 1) radtonu- 
elide measurements of convalescent left ventricular function 
(primary end point. rest function; secondary end pc:nt. 
exercise function), 2) measurements of clinical morbiddy. 
and 3) coronary artery patency at I day. Resuits are gener- 
ally given a~ mean value ? I SE. Separate analy+ of 
function was specified prospectively for panems wrh a first 
acute myocardial incdrction and for thorr with either anterior 
or inferior or other acute myocardia, infarcrion. An impu,ed 
analysis for ejection fraction was also prospectively planned 
to account for patients who died before follow-uo testme. 
Calegoric variables were compared between groups by o&g 
a chi-square test or Fisher exact test when marginal total 
values were small, that is, <5. 
Continous variables were compared berween groups by 
using the unpaired r test, except thax hematologic variables 
measured at various times after therapy were tested by using 
a repeated measures analysis of vanance. Nonparametric 
testS (for example. the Mann-Whitney test) were used for the 
imputed analysis. Adjustment for missing values (imputed 
analysis) WBE made by assigning an ejection fraction of I lrbh 
than the lowest measured value in the treatment groups to 
patients who died betore the convalescent study. Final 
statistical analyses were performed at the central coordinat- 
ing center in Utah by using the StatVies II program on data 
abstracted from case repart forms. 
The composite clinical morbidity index comparison (SO) 
was made by using stzpwix ordinal logistic regression 
(BMDP Statistical Software) (51.52). Drug asstgnment was 
used as the independent variable in the analysis. (The model 
gives a iingle coefficient for drug assignment group. although 
different constants are also determined for each level of the 
dependent variables [morbidity levels].) The odds ratio for 
overall morbidity, comparing the two drug groups. was then 
obtained from the coefficient of the exponential function in 
the model. 
Results 
Eot~ characteristics of twatment groups. A total of 325 
oatkIts were entered into the studv: 161 oatients were 
kndrmized to receive APSAC and 16410 receive rt-PA. The 
APSAC- and r&PA-treated mows were well balanced with 
respect to age. gender, time to’therapy (mean 2.7 h from 
symptom onset), entry b&d pressure and heart rate and 
distribution of infarct-related arteries (Table I). Classitica- 
tion by iofarct site resulted in an identical proportion of 
patients with anterior (37%) and with inferior or other acute 
myocardial infarction (63%) in each treatment group. 
Pretreatment medical history was generally comparable 
in the patients randomized to the two groups. including the 
proportion ofpatients with previous acute myocardial infarc- 
tion (18%). history of hypertension, previous angina. heart 
Table I. Enrry Charackxi~rics and Medical Ht~tory of 325 
failure and ventricular ii&ill&m (Table IL However, dia- 
betes was more frequent in the APSAC than in the r&PA 
group (21% vs. 12%). 
Rest left ventricnk tie&on fmcticm comparisons. Con- 
v~lescent left venrricul~ ejection fraction at the predis- 
charge study end point (measured 7.8 2 0.4 days after 
admission) averaged 51.3% in the APSAC group and 54.2% 
in the d-PA group (p = 0.038) (Fig. I. Table 2). At the 
I-month study (perfonoed at 38 + I.7 days). ejection frac- 
tion averaged 50.2% in the APSAC group verses 54.8% in 
the n-PA group (p = O.GiI2). A substantially depressed 
ejection fraction (<30%) was present at I month in a small 
and similar proportion of APSAC-treated (5%. n = 6) and 
n-PA-treated (5%. n = 6) patients. In contrast to these 
differences at convalescent study. ejection fractions were 
similar at the early (median 2.9 h) post-treatment baseline 
study (Table 2). 
Addi!ional prespecified analyses were performed to as- 
sess the consistency of ~bcse primary outcome results. 
Restricting analysis solely to patients with a first acule 
myocardial infarction yielded differences in group mean 
values paralleling those of all patients, averaging 2.3 
,401 versus 55.5% (n = MO) a, I month (p = 0.007) for the 
APSAL and r&PA groups. respectively. Results were also 
unchanged when an analysis was made using estimates for 
misqing values ior surviving pat~en,~ stratified by anterior 
and inferior acute myocardial infarction. No interaction of 
angioplasty or bypass surgery o” the effec, of drug on 
ejeclion fractior. a, discharge or at I month was observed 
(p = 0.50, p = 0.63, respectively. for interaction of drug by 
procedure). When chonjie in ejection fraction from baseline 
to conva.lescence war computed. differences in outcome 
berween APSAC and n-PA groups were again observed a, 
discharge (P c O.dZ) and at I month b < 0.001). 
(N.139) IN-138) 
Discharge 
(p = 0.12) and 4.2% points (p = 0.012) a, discharge and a, I 
month, respectively. in favor of rt-PA (Table 2). Results of 
comparisons between rest ejection fraction within se,s of 
patients wi,h anlerior and inferior acute myocardial infarc- 
tion in the two drug treatment groups were also similar lo the 
resuks of the overall comparisons. An impuled analysis, 
performed to accoon, for patienta who died before follow-up 
sludy. yielded median ejection fracrxxs of 52% (n = 146) 
versus 54% (n = 149) a, discharge fp = 0.10) and 50.5% ,n = 
Comparability of groups undergo& ejection baetion test- 
ing. D,fferences in outcome could not be explained by a 
study cenfer effect. Results of ejection fraction studies, read 
m the central core laboralory, did no, differ by study site, 
whether sites were considered separately (ANOVR: dis- 
charge p = 0.52, I month study p = 0.86) or gmuped by high 
(>5 patients/site) verse low (55 patients/site) recruitment 
status (discharge p = 0.71, I month study p = 0.89). 
Similarly, the drug effect on ejection fraction was not ex- 
plained by differences in response by study site; specifically, 
no center by drug interaction was found to explain conva 
leecent ejection fraction results (two-way ANOVA: dis- 
charge p = 0.77, I-month study p = 0.62). 
To examine whether differences between treatment 
groups could be explained by differences in basehne vana- 
bles present despite randominatton. stcpwise linear regres- 
sion was p&o&d. forcing baseline. variables intd the 
analysis before the effect of drug assignment was evaluared. 
Variables entered included gender. age. site of acute myo- 
cardial infarction. level of pretreatment ST segment eleva- 
tion, time to therapy, history of angina. hypertension. heart 
failure, previous acute myoeardiaiinfarctibn. diabetes and 
number of diseased V~SSCIS. After adiustment for these 
baseline characteristics. the effect of drug assignnxnt on 
ejection fraction remained significant ar I month (p = 0.007) 
although not at discharge (p = 0.13). 
Concomitant drug therapies did not differ significantly at 
convalescence in the APSAC and rt-PA groups for treatment 
with aspirin (76% and 75%. respectively. at I month). 
nitrates (42% and 45%). beta-blockers (40% and 40%). 
calcium channel blockers (39% and 34%). warfarin (?I% and 
22%). diuretic agents (II% a-d 7%). convening enzyme 
inhibitors (I 1% and 7%) and digitalis 17% and 9%). Average 
rates of maintenance heparin infusions during the hosplral 
stay. adjusted on the basis of @a! th:omboplastin time 
determinations, were also comparable in the IWO groups. 
Mechanical interventions were performed with similar fre- 
quency during follow-up in the two groups lsee later). Rest 
blood pressure (predischargc 122174 vs. 121175 mm Hg; 
l-month study 127177 vs. 128,779 mm Hg) and heart rate 
(predischarge 69 vs. 69 beatslmin; I-month study 73 vs. 70 
beats/mitt). measured at the time of convalescent ejection 
fraction determinations. were similar in the APSAC and 
R-PA groups. 
Results of segmental and ventricular vdume analyses. 
Segmental functional and volumetric analyses suggested that 
the diiierences in ccnv~!csce~t glctal cjccticr. tnaim by 
treatment were explained primarily by differences in infarct 
zone function and end-systolic rather than end-diastolic 
volumes (Table 2). 
Ejection fraction in the infarct zone averaged 37% in the 
APSAC grcmp versus 42.2% in the n-PA group at the 
prcdischarge study (p < 0.02) and 36% versus 42.3% at I 
v~luel. Nunc of the differences between anirtreplase rAPSAC) and 
alteplasc lrl-PAI is slatirtically significant rp > 0.051. 
month Ip < 0.01) (Fig. 2). In contrast, values at the 24-h 
basehne study wcrc similar (38.2% APSAC. 38.7% rt-PA. 
p = 0.80). Noninfarct wne ejection fractions did not differ at 
discharge or at baseline in the two groups but were margin- 
ally in favor of R-PA at L monrh (Table 2,. 
Group mean end-systolic volumes averaged about 8 ml 
more in the APSAC :!a in the n-PA group at both the 
predischarge (p < 0.03) and the l-month study (p < 0.06) 
(Table 21. In contrast. convalescent end-diastolic volumes 
did not differ significantly (Table 2). Baseline values for boih 
end-systolic and end-diastolic volumes rrere similar. 
Exercise left ventrienlnr fwction. On both the predis- 
charge (wbmaximal) and the I-month (maximal) treadmill 
test, exercise rimes were comparable in the two groups (Fig. 
31. Ejection fraction was increased at maximal exercise 
compared with that at rest in both groups (Fig. 3). The 
increase tended to be greater for rtlPA_ at predischargc 
submaximal testing (p = 0.052) but was almost identical 
(+4.3% points vs. 4.6% points. p = 0.80) in the two group, 
at the i-month maximal test. the primary exercise end point. 
Adverse clttical events and combined morbidity index. 
The occurrence of major clinical events WBE gmterally com- 
parable in the APSAC and R-PA groups and was in the range 
anticipated for these thrombolytic regimens, including 
I-month mortality (6% and 8%. respectively), stroke (2% 
and 1%). reinfarctian (2% and 4%). heart failure, recurrent 
ischcmia and ventric&u tachycaniia or fibrillation (Table 3). 
In addition to the six stroke events. there were two transient 
ischemic attacks in the study (bath in the APSAC group). All 
deaths were cardiovascula~and were due to complications of 
acute myucardial infarction (shock or cardiac arrest, n = 191; 
intracranial hemorrhage. n = 3; or pulmonary embolism. 
n = I. The majority of deaths II5 of 231 in both groups 
occurred within I to 2 days. Bleeding events (of any kind) 
occurred commonly in both groups; lransfusions were given 
somewhat more frequently in the APSAC than in the rl-PA 
group (28% vs. 17%). Decreasea in hemoglobin concentra- 
tion with therapy were similar in the two groups. averaging 
2.4 and 2.2 g/d1 in 72 h Ip = 0.2) (Table 4). 
Transient hypotension of any cause during the hospital 
stay (68% vs. 54%) and potential allergic reactions (2.S% vs. 
1.2%) were reported by investigators somewhat more com- 
mon for the APSAC than for the n-PA group. Maximal 
measured diRerences in blood pressure Ip < 0.01) and heart 
rate (p = NSI between the two groups occurred IO min after 
the start of therapy, when they averaged 106169 mm Hg and 
79 bestslmin. rcspecdvely. in the APSAC group versus 
125179 mm Hg and 78 beatsimin in the ISPA group. 
Overall clinical oukome was assessed with a combined 
morbidity index after the method of Califf et al. (50) using 
ordinal logistic regression (51,52). This analysis ranked the 
worsl event for each patient during the hospital stay and 
during the I-month follow-up period using five ordered 
levels: I) death; 2) hemorrhagic or thrombotic or embolic 
stroke; 3) global ejraion fraction 430% or r&faction OF 
heart failure within I month or ventricular fibrillation: 4) 
emergency bypass surgery or ischemic pain or ventricular 
tachycardia: and 5) none of these events. The combined 
morbidity comparison for the IWO drugs showed an equiva- 
lent outcome (Table 5): the odds ratio of all adverse oot- 
comes for APSAC- versus n-PA-treated patients was I.05 
(95% confidence interval. 0.74 to 1.5) (p = 0.82). 
One.dar cormw~ arterv oatencv and correlation with 
ejection f&ion. Coronaryarie~ograpby at the I-day stud,, 
(performed in the APSAC group at a mean of 30 -r 2 h 
[median 26.31 and in !he r&PA group at a mean of 33 c 3 h 
[median 26.51) revealed comparable distributions of TIM1 
perfusion grades 127) in the wo groups (Table 6). Rates of 
total coronary artery patency (TIM1 grade 2 or 3 perfusion) 
were high in both groups (APSAC 89%, R-PA 86% p = 
0.37). Most patients (APSAC 75%. r&PA 73%) showed 
complete (grade 3) perfusion. Success WBF +ai!ar for the 
anterior and inferior acute myocardial infarction groups. 
Quantitatively determined residual stenosis at the site of the 
@sumed h&t-related lesion in patients with coronary 
ar,ery patency was comparable in [he iwo g:ouPs (p = 0.8). 
waging 7 I% to 72%. The interaction of l-day patency and 
drug group assignmem on ejection fraction was not signifi- 
cant. 
Comparative hematologic @eeoEts. Both thrombolytic reg. 
imens resulted in significant decreases in hbrinogen and 
plasminogen thai were maximal at the 4-h study and rccov- 
ered toward baseline within I to ? days (fable 41. As 
expected, compared with rt-PA. APSAC resulted in greater, 
more prolonged reductions of both circulating fibrinogen tto 
26% vs. 65% of baseline) and plasminogen (to 23% vs. to 
58% of baseline). 
Freguettty of mechanical interventions. Mechanical inter- 
ventions, alloned for clinical indications after the l-day 
angiogram. were performed il? equal number after APSAC 
and rt-PA therapy. Caronxy angioplapty was performed 
before discharge in 25% (40 of 161) of APSAC-treated and 
24% (39 of 164) rt-PA-treated patienfs. bypass surgery in 9% 
(n = IS) and 13% (n = 22). respecGvely. and both in 6% 
(n = IO) and 2% (n = 41, respectively. Overall, one or more 
mechanical interventions were used in 40% (65 of 161) of 
APSAC-treated and in 40% (65 of 164) of n-PA-rreated 
patients. Interventions were performed close to the time of 
j-day angiography more fre&ntly in patients with TIM1 
made 0 or I flow Nt% vs. 7% in oatients with TIM1 erade 2 
or 3 Row): later (elective) inte~entions were perfortrted 
more frequently in those with grade 2 or 3 Row and clinically 
significant stenosis (I 1% vs. 34% in patients with TIM1 grade 
0 or I AOW. 
Diicusion 
Study summary. The purpose of this study was to com- 
pare clinical mttcome~ after treatment with APSAC. B re- 
cently approved thrombolytic agent. and n-PA. currently 
the most frequently used tbrombolytic agent for acute myc- 
cardial irJarctio*l in the United Statss. To cnrure valid 
comparisons, the study was designed as a randomized. 
double-blind, double-dummy trial of sufficient size and 
power lo detect clinically impOrtant differences in funct:onal 
outcome. Rest and exercise myocardial function, clinicrd 
murbiduy (overall morbidity index) and Iday (plateau or 
“stable”l coronary anery patency were chosen for evrdua- 
lion. The findings showed that rest left ventricular ejection 
fraction was similar at the very early (G-b1 study but 
diverged by 2% puintr to 4% poin:s 21 discharge and at I 
ntonth in favor of n-PA. These differences were xoiamcd 
by differences in segmental function i  the infarct zdne and 
by ditlcrences in end-systolic rclumcs. In contrast to diller- 
ences in rest function, exercise augmentation of ejection 
fraction was similar at the l-month primary exercise end 
point Tbc incidence of maior clinical events, such as death. 
stroke. congestive heart f&re. seriow arrhythmias. rein- 
fruction and recwrettt ischemia, and the overall morbidity 
index were comparable in the two treatment groups. Coro- 
nary artery patency rates at I day were similarly high after 
APSAC and r&PA (8% and 86%. respectively). and subse- 
quent mechanical interventions were judged to be needed in 
a similar percentage of each group. Bleeding episodes and 
transfusion reqairements were somewhat greater after the 
APSAC plus heparin than after the rt-PA plus heparin 
regimen. 
Consistency of rest ejection fraetioo results. In this study, 
rest ejection fraction differed between treatment groups by 2 
to 4% points, a difference judged prospectively by :bc 
investigators to be of possible clinical significance. The 
reasons for the small drug-related differences are unknown. 
However, the differences were cansistex, even when addi- 
tional analyses were performed. These included testing 
restricted to patients with a tint acme myocardial infarction 
and separate analyses for patients with anterior or inierior 
acute myocardial infarction. Imputed analysis, ivhich ac- 
counts for patients lost to convalescent study because of 
death. yielded asimilar result. Adjustment for differences in 
patient entry characteristics by an analysis of covariance 
also had only a small effect on outcome compari~oss. 
Ejection frzcrion measurements may be subJect to differ- 
ences in loading conditions. In fact. APSAC cattses greater 
vasodilation within the first IO min of therapy than doer 
n-PA (the difference in mean blood presshe is IO to 
15 mm Hg. which gradually resolves). Coweivably. residual 
drug-related hemodynamic effects may have exerted a minor 
influence on the baseline study comparison at a median of 3 h 
after ,r.eatmen,, but any effects would have resolved long 
before performance of the convalescent studies. the primary 
end points, when blood pressures were comparable in the 
two randomized groups. Furthermore, the groups wue 
equivalent in rhcx use of concomitant medications that may 
haw influenrad myocardial performance during these con- 
valescent studies. 
Differences might also bc influenced by slttdy center 
recruitment bias or missing data. No study center e5ects 
were found to explain intergroup differences. Patienrs whose 
data were missing because of death were taken into aecouot 
in the imputed analysis, which did not lead to notably 
dierent results. Otherwise, only 9% to 14% of patients did 
not contribute to the predischarge and I-month restdts; no 
analysis that estimated these missing values also did not 
yield different results. Therefore any influence of study 
center bias or these missing data on the overall comparisons 
in this randomized study should be very small. 
Reasons for dierences in rest ejection fraction. Regional 
and vc!umctric ventriculographic &dyses showed that dif- 
ferences in global ejection fraction could be explained by 
differences in rcgtonal ejection fraction in the infarct woe 
and in end-systolic volumes. Diastolic volumes were com- 
parable. Although I-day coronary artery patency rates were 
similar and did not explain differences in ejection fraction, it 
is possible that very early patency rates tat 530 to 90 min) 
may have shown hifferences in-favor of rt-PA apd may 
provide explanation for the differences in ejection fraction; 
other studies have suggested that thrombolysis may proceed 
more rapidly after treatment with fibrin-selective than with 
nonfib&-selective agents (27.28.53-57). 
Perspective .I functional outcome at rest and previous 
studies. Despiti the small intergroup di5erenc.x the ejec- 
tion fractions in our study averaged >50%, indicaring excel- 
lent rest veotr:, ular function in both treatment groups in 
comparison with that of previous studies of treatment of 
acute myocardia! infarction (3.5.13-16.31,37.SO.SS.58-61~ 
and suggesting that myocardial salvage was achieved. Un- 
like earlier experimental and clinical studies (60.62-64). our 
study provides little evidence for substantial early myocar- 
dial stunning with subTequcnt delayed recovery. Patient 
entry within 4 h of pain onset and treatment at a mean of 
2.7 h of pain may have contributed to this favorable out- 
come. 
One other rattdomized trial 1591 has compared functional 
outcome after treatment with APSAC and rt-PA. That 
French trial, which was smaller than ours (183 vs. 325 
patients). performed only a smgle radionuclide study but was 
otherwise ouitc similar in d&n. In that trial. eiection 
fracttons a&aged 50% after APiAC and 52% after i.PA at 
the 5. i 2.day angiographic study and 47% and 48%. 
respectively. at the I8 5 S-day radionuclide study. The I% 
to 2% point intergroup difference and the small parallel 
trends in reeionsl wall motion and infarct &.e favoring rt-PA 
did no, achieve significance. Earlier, the same group had 
shown a sieniiicant advantwe (avcracinc 6% points) in 
corwalesceo~ ejection fractionaftsr APSAC comt&ed with 
that after placebo plus heparin therapy (16). 
Compakms ofexercis~ function. Exercise performance 
in patients with coronary artery disease and myocardial 
infarction may be limited by reduced myocardial reserve and 
by exertions1 ischemia. In our study. the two drug regimens. 
augmented by equally applied medical therapies and me- 
chanical interventions as clinically mdicatcd. were indirtin- 
guishable in exercise time and increase in exercise ejection 
fraction at the I-month primary end point, despite the small 
diffcrcttccs in rest function. 
Ejection fraction and ventricular volumes as end points 
after thrombolysis. Interest in ejection fraction after acute 
myocardial infarction derives from its excellent predictive 
value for mortality i? the era before thmmbolysis (58.65). 
White et al. (65) foutti? that end-svstolic volume. as well as 
end-diastolic volume, ‘was an evenstrongerprognostic factor 
for subsequent death than was global ejection fraction. In the 
era of thrombalytic therapy. the clinical implications of 
ejection fraction outcomes have been debated (50.66). Ejec- 
tion fraction has been frequently used as a marker of 
functional benefit. myocardial salvage and infarct healing. 
Moreover. because global function may be influenced by 
noninfarct zone processes (such as compensatory hyperki- 
nesia in the normal zone), e5ects of interventions in the 
infarct nme have been the focus of specific intcrcst, as in our 
study. However, until recently the&has been relatively little 
information on the predictive value ofejection fraction in the 
setting of thrombolytic therapy. 
lo a preliminary report on about 3.ooO patients from the 
TIMI-II study. Zaret et al. (67) found that left ventricular 
ejection fraction remains an important prognostic index in 
patients who have received thrombolytic therapy, but the 
mortality rate is lower at any level of ejection fraction than 
was noted before tbrombolytic tbeapy became available to 
oatients. In TIMI-Il. the eiection fraction-mortalitv ewe 
was shifted downward. so &at only at an ejection fraction of 
430% did the mortality rate at I year increase significantly. 
We were unable to di5erentiate patients treated with APSAC 
or R-PA on the basis of very low (<30%) ejection fraction 
outcomes (six such outcomes were noted in each group). 
Comparisons of clinical outcome and morbidity index after 
APSAC and r&PA therapy. Califf et al. (50) and others (32) 
have summarized problems inherent in using ejection frac- 
tion as a surrogate for clinical study end points (SKII as 
death) in thrombolysis comparisons and have propose” the 
use ofa combined clmical end poix analysis as another G’P; 
10 asress the response to therapy I” comparative to& of 
intermediate size. Accordingly..wc cv&ed clinical mor- 
bidity as one of our clinical end points. Whelher adverse 
events were assessed separately (Table 3) or overall. with a 
composite morbidity index (Table S). a comparable result 
was obtained for patients treated with APSAC and rt-PA. 
Because trials of sufficient size to determine mortality d!f- 
ferences are impractical for every new treatment regimen 
and because the clinical implications of differences in arterial 
patency profiles and ejection fraction results are not yet 
clear. such an approach has become increasingly appealing 
as a method of comparing clinical outcomes. 
Cwonary artery patency after APSAC and &PA. Rees- 
tablishment and maintenance of coronar:~ blood Row in the 
infarct-related coronaw artery are believed to reorrsent a 
major mechanism of thromb&sis benefit (68). 1. clinical 
studies, patency has been most commonly determined at 
90 mi” after therapy. However, controversy has developed 
on the optimal end point for coronary artery patency mea- 
surements when comparing treatment regimens, give” the 
apparent failure of differences in the traditional ‘N)-min 
results to predict relative mortality outcomes (27.28.32.33). 
Sherry and Marder (53) recently proposed that a stable or 
“plateau” patency rate achieved somewhat later than 60 to 
90 mi” but within a few hours to I day may be a better 
predictor oi mortality than patency assessed at 90 min. 
I” our study, angiography was performed at I day to 
avoid the early confounding of comparisons of left ventric- 
ular functional outcome by the frequent use of emergency 
acgioplasty or surgery that inevitably follows angiographic 
assessments (“oculostenotic r&x” or “reperfusion “to- 
menturn”) (69). Also, it was recqnized that 90min coronary 
artery patency had already been extensively assessed for the 
two regimens and averaged 70% to 75% for standard regi- 
mensofboth age”tsf27-30,54,70,71). Front-loaded regimens 
of r&PA may result in eve” higher early patency rates than 
those ashieved with standard infusions of rt-PA or APSAC 
(57.72.73) and deserve ?tiher testing. 
Our study shows that at I day, coronary artery patency 
rates for both drugs (8% and 86% for APSAC and r&PA. 
respectively) are eve” higher than early patency rates re- 
paled (27-30,X70,71) for thx drugs, suggesting that 
within the 1st day, ongoing :rbri”olysis zmd repelfusion 
outweigh thrombotic reocclusio” for the regimens we tested. 
Concomitant antithrombotic therapy (aspirin, intravenous 
hepari”) may have been impcrtant in maintaining and rug- 
mentine patency. especially after n-PA treatment, in view of 
results of recent trials showing lower patency rates at I day 
when rt-PA was not given with intravenous hepdrin (34,36). 
Although I-day patency has been proposed as a predictor of 
survival benefit (53). it did “at distinguish drug-related 
ditferences in ejection fraction in our study. 
Hematdt@c offeeb. As expected from their phamtaco- 
logic differences (5,24,25), APSAC and &PA bad quantita- 
tively different effects on coagulation factors. The trend to 
slight!y higher bleeding rates and “tore transfusions in the 
APSAC group than were observed in the rl-PA group or in 
previous erperience (20.30.49) may be explained by the 
earlier “se of intravenot!s heparin (begun at 2 h. rather than 
at the bh used in many stttdies 120.251) and the addition of 
aspirtn therapy. For simplicity of study design. hepari” was 
administered after 2 h to maintain blinding and to optimize 
the rt-PA regimen. Because of APSAC’s long half-life (90 to 
I20 mini. heparin is usually given ~6 h after APSAC 
administration in clinical practice and may not be required at 
all (74). Delaying or omitting heparin afkr APSAC adntinis- 
tliltlon should thus be considered to avoid excessive risk of 
bleeding. 
Relation antottg end points. Differing relative outcomes 
among end points are not new to this stody. Cc;.trz.tb; 
rewIl5 among indexer of coronary artery patency, left 
ventricular function and mnrtnlity have z!w been noted in 
other comparative trials ~27.28,32.33.36.5053.75,76). In this 
study. interdrttg comparisons among left venhicular rest 
function. eaercise function, morbidity and patency gave 
different results, which sttggests that the interrelations 
among these end points and the relation of thrombolytic 
therapv and clinical outcome are complex. Until a better 
understanding of the clinical implications of these end 
points and their interrelations is achieved, it is reasonable 
to view each as a distinct aspect of the overall outcome 
profile rather than to accept any as a true surrogate for the 
others. 
Limitations. Our study tested two treatment strategies, 
not just two drugs. Each strategy began with a different 
thrombolytic drug attd was then augmented by ancillary 
medications (aspirin and heparin) and procedures. which 
is <be comtttat practice in our centers. However, these 
medications and procedures were used equally in both 
groups and interventions occurred only after the 1st day. 
the time when drug-related differences are likely to have 
been most important. I” fact. no irerxtive effect of 
angioplasty or surgery on ejection fraction difference by 
drug group was observed. Also. the use of additional thera- 
pies to optimize outcome would have been expected to 
diminish rather than increase a”~ initial diierences between 
groups. The study size was too s&l to test fwditferences in 
motialitv rate but was adequate to assess clintcallv imwr- 
tant differences in the chose” primary fu”ctia”al,~pat~“cy 
and combined clinical morbidity index end wints. The study 
did not address the issue of &ts, which may be of clinic2 
impwtance in drug selerticn and which diier among tbrom- 
bolytic “gents. The approximate phanacy costs for stan- 
dard doses are $1.700 for anistreplase: $2,200 for alteplase 
and $300 fm stteptokinase. Despite these timitatinns. !br 
studv findines mav be of snecial relevance to North Ame& 
can .physi&“s. because’ recent large mortality studies 
(32.33.36) did not “se coniunctive medical theraw (such as 
intravenous hepari” with >-PA) and intervent& common 
to their practice. 
Condusions. TEAM-3 has compared standard regimens 
of APSAC and n-PA in a randomized. blLded. controlled 
trial. Rest ejection fraclion. the prmwy end point. measured 
at discharge and at I month, favored n-PA by small ddkr- 
aces (2% points lo 4% points) that were due lo differences 
in infarct zone function and end-systolic volumes. Convales- 
cent ejection fraction was excellent in both groups 050%) 
and exercise function was comparable. Clinical outcomes 
were also comparable and favorable, as assessed by the 
clinical morbidity index. and I-day coronary artery patency 
was high and similar in both groups. Longer-term observa- 
tions and larger trials will be helpful in clarifying the impli- 
cations of these findings. 
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